Position in NVAX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$947,265
-$110,935 QoQ
Shares Held
100,559
-22.6% QoQ
Ownership
0.061%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#65
of 263 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NewEdge Wealth, LLC holds $28,019,722 across 22 Biotechnology names. NVAX ranks #7 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
11,305 | $5,615,532 | |
| 2 | BHVN |
Biohaven Ltd.
|
245,670 | $3,655,569 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
34,890 | $3,033,685 | |
| 4 | EXEL |
Exelixis, Inc.
|
51,642 | $2,809,841 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,094 | $2,737,566 | |
| 6 | INVA |
Innoviva, Inc.
|
99,367 | $2,256,624 | |
| 7 | NVAX |
Novavax Inc
This page
|
100,559 | $947,265 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
22,562 | $880,143 |
All Filings in NVAX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $947,265 | 100,559 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $1,058,200 | 130,000 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $875,206 | 130,239 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $1,473,900 | 170,000 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $1,100,925 | 174,750 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $1,153,832 | 180,005 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $1,367,740 | 170,117 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $1,263,000 | 100,000 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,266,000 | 100,000 | Shares | Sole | 2024-08-02 | |
| No filing history on record for this holder in this stock. | ||||||